temp_copy

Image courtesy of Gillian Hue. The AJOBN Editorial team recently returned from the 11th annual International Neuroethics Society (INS) meeting, which took place on November 9-10th in Washington, DC. The theme for the meeting was Honoring our History, Forging our Future , and it brought together scientists, philosophers, professionals, and scholars from over 10 countries to both summarize the first 15 years of the neuroethics field and to discuss our prospective future. The day and a half conference included plenary lectures, a public forum, panel discussions, and a poster session, and addressed topics ranging from the development of lying in children to the neuroethical considerations that accompany the use of transcranial direct current stimulation ( tDCS ). In case you didn't get the chance to attend the conference this year, here is a brief summary of what you missed (a full program recap can be found here ). Image courtesy of Gillian Hue. The conference opened on Thursday a...

By Sarika Sachdeva This post was written as part of a class assignment from students who took a neuroethics course with Dr. Rommelfanger in Paris of Summer 2016. Sarika Sachdeva is an undergraduate junior at Emory studying Neuroscience and Behavioral Biology and Economics. She is involved with research on stimulant abuse and addiction under Dr. Leonard Howell at Yerkes National Primate Research Center. Researchers around the world are working to develop treatments and cures for all kinds of genetic disorders and abnormalities, but what happens when the people affected by the condition don’t want it taken away? New breakthroughs in treatment are often controversial for non-fatal conditions such as Down Syndrome , which causes inhibited neural communication and leads to learning delays as a result of an extra copy of chromosome 21 ( Rochman, 2015 ). Recently, a study from the Boston University Medical Center claimed to have identified differences in gene expression that ar...